Jean Bouquet de Joliniere1*†
Arrigo Fruscalzo1†
Fathi Khomsi1
Emanuela Stochino Loi1
Floryn Cherbanyk2
Jean Marc Ayoubi1,3
Anis Feki1- 1Department of Gynecology and Obstetrics, University Hospital of Fribourg, Fribourg, Switzerland
- 2Department of General Surgery, University Hospital of Fribourg, Fribourg, Switzerland
- 3Department of Obstetrics and Gynecology and Reproductive Medicine, Hôpital Foch, Suresnes, France
Angiogenesis plays a pivotal role in implantation and development of ectopic endometrial lesions. Thus, the potential usefulness of anti-angiogenic therapies has been speculated. Several reports describe their usefulness in animal models. Nonetheless this therapy has not been tested on humans yet. Here we report the outcome of a patient treated for a severe endometriosis with Bevacizumab (Avastin®), a monoclonal antibody directed against the vascular endothelial growth (VEGF). After a first-look laparoscopy with confirmatory biopsies was performed, three doses of Bevacizumab at 2-week intervals were administered. The therapy showed a well-tolerated profile and the prompt disappearance of the therapy-refractory chronic dysmenorrhea. A suppression of metabolic activity at the PET-scan compared to the basal one performed at diagnosis was also recorded. Furthermore, compared to the diagnostic biopsies prior the treatment, we documented a shift in the hormonal receptors profile toward a higher expression of progesterone and estrogen receptors in the endometriotic lesions.
Introduction
Endometriosis is a benign disease characterized by ectopic endometrial implants outside the endometrium. It seems to affect about 5–10% of women of reproductive age, though its presence is often underestimated as clinical manifestations are heterogenic and diagnosis remains challenging (1). Importantly, if not adequately treated, endometriosis can develop over time into a potentially very disabling disease characterized by a wide spectrum of symptoms including severe chronic pelvic pain, subfertility or infertility as well as destruction of anatomical structures and organs, depending on site of implantation and extension (2, 3).
Current therapeutic options mostly rely on hormonal therapies, progestogen-only or combined estrogen-progestogen pills and GnRH analogs, administered to block ovarian function and avoid perimenstrual pain (4). Nonetheless, this conservative therapy can in some cases be unsuitable or even fail, necessitating the surgical removal of implants that implies the considerable intra- and post-operative issues linked to such a destructive surgery. This scenario occurs in most advanced forms of endometriosis linked to chronic and therapy-refractory pain and organ disruption (5).
Bevacizumab (Avastin®) is a monoclonal antibody directed against the vascular endothelial growth (VEGF) (6). As angiogenesis is one of the predominant factors involved in implantation and development of ectopic endometrial implants we speculated on its potential usefulness in the treatment of endometriosis (7). Animal experiments showed potential beneficial effects both in the therapy and in the prophylaxis of development of endometriosis-like lesions (8). Nonetheless, its potential usefulness on humans has not been tested to date.
Here we report the outcome of a patient affected by a severe form of endometriosis infiltrating the rectosigmoid and the pelvic wall and treated with Bevacizumab before surgical removal of the endometriosis nodule. The clinical, the metabolic activity at the PET-scan and the immunological profile at histochemistry before and after the adjuvant therapy have been evaluated.
The Clinical Case
This case refers to a 46-year-old patient, admitted to emergency for acute pelvic pain with recto sigmoid mass and mechanical ileus. An abdominal CT scan performed in emergency showed colonic dilation with a stenosing tumor-like mass at the recto-sigmoid bordering the left ovary. The patient was hospitalized in the surgical department for clinical monitoring and further assessment. The next day, the patient developed an acute peritonitis requiring an emergency laparoscopy. In consideration of the suspected malignant origin of the mass stenosing the recto-sigma, the general surgeons performed a temporary transversostomy for bypassing the intestinal obstruction.
Subsequently the patient was discharged. A PET scan requested for differential diagnosis revealed a recto sigmoid hypercaptation, suggesting a primary intestinal tumor without evidence of lymph node metastases (Figure 1). A colonoscopy with biopsies was performed, showing a recto-sigmoidal stricture, without any evidence of cancerous lesions.
Figure 1. 18F-FDG PET-CT, pre-treatment with Bevacizumab: intense recto-sigmoid hypercaptation (circled in blue) without further hypermetabolic lesions.
Thereafter, a diagnostic laparoscopy was performed, revealing a deep infiltrating endometriosis of the recto-sigmoid with involvement of the left pelvic wall and adnexa. The removal of the left adnexa for histopathology was undertaken, while the severity of the infiltration required the postponement of a curative surgical treatment. A series of further biopsies were taken for histological examination, which confirmed the diagnosis of endometriosis.
Faced with a positive anamnesis of invaliding dysmenorrhea despite the use of a combined oral contraceptive pill since the age of 25, the “off label” treatment with three doses of 5 mg/Kg intravenous Bevacizumab (Avastin®) at 2-week intervals to control pain relapse was proposed. No dyschezia, nor dyspareunia, chronic pelvic pain or menstrual abnormalities were reported in the anamnesis. An informed consent was signed. A good tolerability profile of Bevacizumab was observed, without any side-effects registered during and after its administration. Importantly, the complete disappearance of dysmenorrhea was observed at the end of therapy. A second PET-scan was then performed, highlighting the suppression of metabolic activity of the endometriotic nodule in the pelvis.
One month after the last dose of Bevacizumab, a second-look intervention with recto-sigmoid resection, removal of residual endometriosis and contralateral adnexectomy was performed. Macroscopically, endometrial lesions remained unchanged in dimension. However, they healed in a fibrous fashion that made dissection difficult. Histopathology confirmed a diffuse fibrosis. Interestingly, compared to the pre-treatment biopsies, a shift in the hormonal receptors profile toward a higher estrogen, progesterone and androgen receptors expression was highlighted (Table 1).
Table 1. Immunohistochemical characterization of endometriosis lesions.
Currently, at 6-month follow-up, the protective transversostomy has been removed and the patient is symptoms-free under a continuous combined hormonal substitutive therapy. Informed consent was obtained from the patient for the publication of this case report (including all data and images).
Discussion
This is the first report of the use of Bevacizumab (Avastin®) in the treatment of a patient affected by endometriosis.
Bevacizumab is a monoclonal anti-angiogenic antibody directed against the VEGF. It thus has the potential to impact one of the most important features of endometriosis, the neo-angiogenesis. Keeping in mind this background, we proposed this therapy as off-label to a patient with a severe form of endometriosis, refractory to conventional therapies.
According to this report, a favorable effect on pain control and an excellent tolerability profile were obtained. Importantly, we observed an increased expression of hormonal receptor in endometriosis tissue. These results could be of high clinical relevance, knowing the central role played by progestins in inhibition of cell proliferation, inflammation and neovascularization (9). Reverting refractoriness to conventional hormonal therapy could help toward a conservative approach to the pathology.
Furthermore, we recorded a good profile of tolerability, without side effect. Nonetheless, due to its anti-angiogenic activity, Bevacizumab should be administered with caution, being linked to cardiovascular, renal and intestinal side-effects (10). A deficient wound healing linked to the treatment with anti-angiogenesis agents should be also kept in mind when planning a second-look surgery. Finally, according to our experience, an increased tissue fibrosis could impact the surgery. Less bleeding, but a greater difficulty of implants dissection due to fibrosis should be considered (11).
Current therapeutic options mostly rely on conservative hormonal therapies. Hereby, combined hormonal therapy and, especially, progestins seems to represent the cornerstone of medications, being also able to inhibit cell proliferation, inflammation, neurogenesis and neovascularization in endometriosis (12, 13). However, for yet unclear mechanisms, some forms seem to be characterized by progesterone resistance, being thus refractory to conventional medical therapy (14). In these cases, GnRH analogs could be proposed as second line therapy, but only for a limited period of time, due to their unfavorable side-effects profile (15).
Searching for new therapeutic options for refractory endometriosis to avoid destructive surgery should be a leading research topic for the future. In this prospective, the conservative treatment with Bevacizumab could be of interest where the conventional hormonal therapy failed, especially if progesterone and estrogen receptors are reduced or even absent. In this light, the results we present seem to be worthy of interest.
Animal experiments already showed beneficial effects both in the treatment and prophylaxis of endometriosis relapse (16–21). The effect of vascular endothelial growth factor inhibition on the volume of endometrial implants was described by all these authors. Furthermore, according to Ricci et al., Bevacizumab significantly inhibited cell proliferation in lesions, reduced vascular density and increased the apoptotic cell percentage (16). Also, Kebapcilar et al. showed higher reduction for the glandular epithelium and uterine vessels compared to controls treated with progesterone (18). Interestingly, Bevacizumab treatment did not affect ovarian reserve assessed by follicle quantification at histochemistry of ovarian serial sections (21).
However, even though these results in mice models were promising, potential usefulness of Bevacizumab on humans remains speculative at this stage. Indeed, the lesions created in rats were obtained from a transplant of endometrial tissue into the peritoneum and may not correspond to the pathophysiology of spontaneous disease in humans (22). Furthermore, vascular activity of endometriotic lesions could potentially affect the therapy efficacy. Indeed, endometriosis is a heterogeneous disease with different types of lesions, both the more active, red ones, as well as the older black and white ones (23). Recent research provided evidence for different patterns of vascularization, also for deep infiltrating bowel nodules. Interestingly, macroscopic features examined by using indocyanine green during surgery were consistently associated with characteristics of vascularization at histopathology (24, 25).
Thus, despite positive results recorded in this report, further studies should be performed to better evaluate clinical and biological results and define the optimal schema for treatment. Importantly, potential systemic negative effects of anti-angiogenic therapy should also be monitored, including ovarian reserve and fertility preservation. Once efficacy and safety of Bevacizumab treatment have been provided, clinical studies should evaluate its potential therapeutic impact in the future, also in the less advanced forms and in the prophylaxis of relapse of endometriosis.
Conclusions
Fighting angiogenesis in cases of endometriosis refractory to conventional hormonal therapy seems a promising option to be evaluated in the near future. Further studies should be performed to better evaluate clinical and biological impact of this potential treatment option.
Data Availability Statement
The original contributions presented in the study are included in the article. Further inquiries can be directed to the corresponding author.
Ethics Statement
Informed consent was obtained from the patient for the publication of this case report (including all data and images).
Author Contributions
JB and AFe: substantial contributions to conception, analysis, and interpretation of data. JB and AFr: drafting the article. JB, AFr, FK, ES, FC, JA, and AFe: substantial contributions to interpretation of data and revising the article for important intellectual content. All authors read and approved the final manuscript.
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher's Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Taylor HS, Kotlyar AM, Flores VA. Endometriosis is a chronic systemic disease: clinical challenges and novel innovations. Lancet Lond Engl. (2021) 397:839–52. doi: 10.1016/S0140-6736(21)00389-5
2. Chapron C, Chopin N, Borghese B, Foulot H, Dousset B, Vacher-Lavenu MC, et al. Deeply infiltrating endometriosis: pathogenetic implications of the anatomical distribution. Hum Reprod. (2006) 21:1839–45. doi: 10.1093/humrep/del079
3. Fruscalzo A, Stochino E, Pluchino N, Bouquet de Jolinière J, Feki A. La nouvelle classification de l'endométriose révisée selon #Enzian: finalement une nomenclature complète et efficace? J Für Gynäkol Endokrinol. (2021) 24:93–7. doi: 10.1007/s41975-021-00194-z
4. Ruhland B, Agic A, Krampe J, Diedrich K, Hornung D. Innovations in conservative endometriosis treatment: an updated review. Minerva Ginecol. (2011) 63:247–59.
5. Bulun SE, Cheng Y-H, Pavone ME, Xue Q, Attar E, Trukhacheva E, et al. Estrogen receptor-beta, estrogen receptor-alpha, and progesterone resistance in endometriosis. Semin Reprod Med. (2010) 28:36–43. doi: 10.1055/s-0029-1242991
6. Chellappan DK, Leng KH, Jia LJ, Aziz NABA, Hoong WC, Qian YC, et al. The role of bevacizumab on tumour angiogenesis and in the management of gynaecological cancers: a review. Biomed Pharmacother. (2018) 102:1127–44. doi: 10.1016/j.biopha.2018.03.061
7. Laschke MW, Menger MD. Basic mechanisms of vascularization in endometriosis and their clinical implications. Hum Reprod Update. (2018) 24:207–24. doi: 10.1093/humupd/dmy001
8. Nap AW, Dunselman GAJ, Griffioen AW, Mayo KH, Evers JLH, Groothuis PG. Angiostatic agents prevent the development of endometriosis-like lesions in the chicken chorioallantoic membrane. Fertil Steril. (2005) 83:793–5. doi: 10.1016/j.fertnstert.2004.06.080
9. Li Y, Adur MK, Kannan A, Davila J, Zhao Y, Nowak RA, et al. Progesterone alleviates endometriosis via inhibition of uterine cell proliferation, inflammation and angiogenesis in an immunocompetent mouse model. PLoS ONE. (2016) 11:e0165347. doi: 10.1371/journal.pone.0165347
10. Sanborn RE, Sandler AB. The safety of bevacizumab. Expert Opin Drug Saf. (2006) 5:289–301. doi: 10.1517/14740338.5.2.289
11. Chu S-J, Zhang Z-H, Wang M, Xu H-F. Effect of bevacizumab on the expression of fibrosis-related inflammatory mediators in ARPE-19 cells. Int J Ophthalmol. (2017) 10:366–71.
12. Mabrouk M, Frascà C, Geraci E, Montanari G, Ferrini G, Raimondo D, et al. Combined oral contraceptive therapy in women with posterior deep infiltrating endometriosis. J Minim Invasive Gynecol. (2011) 18:470–4. doi: 10.1016/j.jmig.2011.04.008
13. Sharara FI, Kheil MH, Feki A, Rahman S, Klebanoff JS, Ayoubi JM, et al. Current and prospective treatment of adenomyosis. J Clin Med. (2021) 10:3410. doi: 10.3390/jcm10153410
14. Patel BG, Rudnicki M, Yu J, Shu Y, Taylor RN. Progesterone resistance in endometriosis: origins, consequences and interventions. Acta Obstet Gynecol Scand. (2017) 96:623–32. doi: 10.1111/aogs.13156
15. Della Corte L, Barra F, Mercorio A, Evangelisti G, Rapisarda AMC, Ferrero S, et al. Tolerability considerations for gonadotropin-releasing hormone analogues for endometriosis. Expert Opin Drug Metab Toxicol. (2020) 16:759–68. doi: 10.1080/17425255.2020.1789591
16. Ricci AG, Olivares CN, Bilotas MA, Meresman GF, Barañao RI. Effect of vascular endothelial growth factor inhibition on endometrial implant development in a murine model of endometriosis. Reprod Sci Thousand Oaks Calif. (2011) 18:614–22. doi: 10.1177/1933719110395406
17. Soysal D, Kizildag S, Saatli B, Posaci C, Soysal S, Koyuncuoglu M, et al. A novel angiogenesis inhibitor Bevacizumab induces apoptosis in the rat endometriosis model. Balk J Med Genet. (2014) 17:73–80. doi: 10.2478/bjmg-2014-0077
18. Kebapcilar AG, Ilhan TT, Dursunoglu D, Kebapcilar L, Ipekci SH, Baldane S, et al. Efficacy comparison of oral rosuvastatin versus oral progesterone and Bevacizumab on regression of surgically endometriotic implants in rats. Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol. (2017) 33:923–7. doi: 10.1080/09513590.2017.1320384
19. Işik H, Moraloglu O, Kilic S, Seven A, Caydere M, Batioglu S, et al. Recombinant humanized monoclonal antibody for treatment of endometriosis in a rat model. J Endometr. (2011) 3:143–50. doi: 10.5301/JE.2011.8724
20. Zani ACT, Valerio FP, Meola J, da Silva AR, Nogueira AA, Candido-Dos-Reis FJ, et al. Impact of Bevacizumab on experimentally induced endometriotic lesions: angiogenesis, invasion, apoptosis, and cell proliferation. Reprod Sci Thousand Oaks Calif. (2020) 27:1943–50. doi: 10.1007/s43032-020-00213-7
21. Ozer H, Boztosun A, Açmaz G, Atilgan R, Akkar OB, Kosar MI. The efficacy of Bevacizumab, sorafenib, and retinoic acid on rat endometriosis model. Reprod Sci Thousand Oaks Calif. (2013) 20:26–32. doi: 10.1177/1933719112452941
22. Hibaoui Y, Feki A. Organoid models of human endometrial development and disease. Front Cell Dev Biol. (2020) 8:84. doi: 10.3389/fcell.2020.00084
23. Harirchian P, Gashaw I, Lipskind ST, Braundmeier AG, Hastings JM, Olson MR, et al. Lesion kinetics in a non-human primate model of endometriosis. Hum Reprod Oxf Engl. (2012) 27:2341–51. doi: 10.1093/humrep/des196
24. Seracchioli R, Raimondo D, Arena A, Zanello M, Mabrouk M. Clinical use of endovenous indocyanine green during rectosigmoid segmental resection for endometriosis. Fertil Steril. (2018) 109:1135. doi: 10.1016/j.fertnstert.2018.02.122
Keywords: endometriosis, VEGF, Bevacizumab, anti-angiogenesis, case report, Avastin
Citation: Bouquet de Joliniere J, Fruscalzo A, Khomsi F, Stochino Loi E, Cherbanyk F, Ayoubi JM and Feki A (2021) Antiangiogenic Therapy as a New Strategy in the Treatment of Endometriosis? The First Case Report. Front. Surg. 8:791686. doi: 10.3389/fsurg.2021.791686
Received: 08 October 2021; Accepted: 08 November 2021;
Published: 06 December 2021.
Edited by:
Zaleha Abdullah Mahdy, National University of Malaysia, MalaysiaReviewed by:
Diego Raimondo, University of Bologna, ItalySvend Lindenberg, Copenhagen Fertility Center, Denmark
Copyright © 2021 Bouquet de Joliniere, Fruscalzo, Khomsi, Stochino Loi, Cherbanyk, Ayoubi and Feki. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jean Bouquet de Joliniere, Ym91cXVldC1kZS1qb2xpbmllcmUuamVhbiYjeDAwMDQwO29yYW5nZS5mcg==
†These authors have contributed equally to this work